

## **Amendments to the Claims**

### **Listing of the Claims:**

This Listing of the Claims will replace all prior versions, and listings of the claims in the application.

1-124 (Cancelled).


125. (Presently Amended): A hapten-carrier conjugate comprising

at least one hapten ~~derived from nicotine, wherein the hapten is nicotine~~ which is nicotine, a nicotine derivative or a salt thereof; and

at least one carrier which is a ~~bacterial toxin containing a T-cell epitope~~ and

wherein said hapten and said carrier are linked by a branch selected from the group of chemical moieties identified by CJ reference number consisting of:

CJ 0	Q
CJ 1	$(CH_2)_nQ$
CJ 1.1	$CO_2Q$
CJ 1.2	COQ
CJ 1.3	$OCH_3$
CJ 2	$OCO(CH_2)_nQ$
CJ 2.1	$OCOCH=Q$
CJ 2.2	$OCOCH(O)CH_2$
CJ 2.3	$OCO(CH_2)_nCH(O)CH_2$
CJ 3	$CO(CH_2)_nCOQ$
CJ 3.1	$CO(CH_2)_nCNQ$
CJ 4	$OCO(CH_2)_nCOQ$
CJ 4.1	$OCO(CH_2)_nCNQ$
CJ 5	$CH_2OCO(CH_2)_nCOQ$
CJ 5.1	$CH_2OCO(CH_2)_nCNQ$
CJ 6	$CONH(CH_2)_nQ$
CJ 7	$Y(CH_2)_nQ$
CJ 7.1	$CH_2Y(CH_2)_nQ$
CJ 8	$OCOCH(OH)CH_2Q$
CJ 8.1	$OCO(CH_2)_nCH(OH)CH_2Q$
CJ 9	$OCOC_6H_5$
CJ 10	<u>as identified in the application as FIG. 2b</u>



, wherein Q' is a modified  
protein;  
YCO(CH<sub>2</sub>)<sub>n</sub>COQ

CJ 11

and wherein for each branch, n is independently an integer; Y is S, O, or NH; and Q is the carrier; is selected from the group consisting of: a protein or peptide carrier, modified protein or peptide carrier, or another branch identified by its "CJ" reference number.

126. (Previously Presented): The hapten-carrier conjugate of claim 125, wherein n is from 3 to 20.

127. (Cancelled).

128. (Previously Presented): The hapten-carrier conjugate of claim 125, wherein greater than one hapten is coupled to the carrier.

129. (Presently Amended): The hapten-carrier conjugate of claim 125, wherein the carrier is ~~cholera toxin B, diphtheria toxin, tetanus toxoid, pertussis toxin, filamentous hemagglutinin, Shiga toxin, pseudomonas exotoxin, ricin B subunit, abrin, sweet pea lectin, retrovirus nucleoprotein, rabies nucleoprotein, tobacco mosaic virus, cauliflower mosaic virus, vesicular stomatitis virus nucleocapsid protein, poxvirus subunit, Semliki forest virus vector or yeast virus like particle.~~

130. (Cancelled).

131. (Previously Presented): A pharmaceutical preparation comprising the hapten-carrier conjugate of claim 125, and a pharmaceutically acceptable excipient.

132. (Previously Presented): The pharmaceutical preparation of claim 131, further comprising an adjuvant.

133. (Previously Presented): The pharmaceutical preparation of claim 132, wherein the adjuvant is alum or RIBI adjuvant.

134. (Previously Presented): The pharmaceutical preparation of claim 133, wherein the adjuvant is alum.

135. (Previously Presented): The pharmaceutical preparation of claim 134, wherein the alum is aluminum hydroxide or aluminum phosphate.

136. (Previously Presented): The pharmaceutical preparation of claim 131, further comprising an auxiliary agent or supplementary active compound.

137. (Previously Presented): The pharmaceutical preparation of claim 131 which is suitable for parenteral administration to a human.

138. (Previously Presented): The pharmaceutical preparation of claim 131 which is suitable for oral, dermal or topical administration to a human.

139. (Previously Presented): A pharmaceutical preparation comprising the hapten-carrier conjugate of claim 130, and a pharmaceutically acceptable excipient.

140. (Previously Presented): The pharmaceutical preparation of claim 139 further comprising an adjuvant.